Market Overview - On May 22, A-shares experienced a collective pullback, with the Shanghai Composite Index down 0.22% closing at 3380.19 points, the Shenzhen Component Index down 0.72% at 10219.62 points, and the ChiNext Index down 0.96% at 2045.57 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.1027 trillion yuan, a decrease of 70.8 billion yuan compared to the previous day [1] - The market showed a broad decline across various sectors, with notable drops in battery, non-metal materials, engineering consulting services, automotive services, professional services, beauty care, instrumentation, electronic chemicals, and food and beverage sectors [1] Sector Performance - The banking sector index reached a historical high, contrasting with the overall market decline [1] - The military and banking sectors were the best performers, with military stocks benefiting from U.S. President Trump's announcement regarding the "Iron Dome" missile defense system, which is set to be operational in three years [2] - The banking sector's rise was supported by the continuation of interest rate cuts and its role in stabilizing the market [2] Technical Analysis - The Shanghai Composite Index is approaching a critical point, with the 5-day moving average about to cross below the 10-day moving average, indicating potential volatility ahead [2] - There are two possible scenarios for the upcoming trading days: either a breakout with increased volume leading to a bullish trend or a lack of upward momentum resulting in a bearish trend [2] - Concerns include reduced trading volume and a net outflow of over 41.2 billion yuan from major funds on May 22, which could indicate a downward trend if these conditions persist [2] Company Spotlight: Jiuzhitang - Jiuzhitang, a company specializing in the production and sales of hepatitis and blood supplement medications, saw its stock rise by 3.88% on a day when only 15 out of 146 stocks in the region increased [3] - The company reported earnings per share of 0.14 yuan and a net profit of 116.5485 million yuan for Q1 2025, with a year-on-year net profit growth rate of -19.40% [3] - Jiuzhitang has successfully removed its ST designation and is progressing with clinical research on stem cell treatments, having established a GMP-compliant stem cell R&D production base in Beijing [3]